Public Citizen chastises FDA for approval of aducanumab in US

Public Citizen called for resignation of more FDA officials involved with approval of aducanumab. In a letter, it stated FDA should have rejected aducanumab until additional clinical data could be produced to support an approval & expressed concern over $56,000 annual list price.

Source:

Biospace Inc.